Askari FK, Greenson J, Dick RD, et al. Treatment of Wilson's disease with zinc. XVIII. initial treatment of the hepatic decompensation presentation with trientine and zinc. J Lab Clin Med. 2003;142:385-390.
Nazer H, Ede RJ, Mowat AP, et al. Wilson's disease: clinical presentation and use of prognostic index. Gut. 1986;27:1377-1381.
Brewer GJ. Wilson's disease: a clinician's guide to recognition, diagnosis, and management. Boston, MA: Kluwer Academic Publishers, 2001.
Scheinberg IH, Sternlieb I. Wilson's disease. In: Smith LHJ, ed. Major problems in internal medicine. Vol 23. Philadelphia, PA: WB Saunders, 1984:1-171.
Brewer GJ, Dick RD, Johnson VD, et al. Treatment of Wilson's disease with zinc: XV long-term follow-up studies. J Lab Clin Med. 1998;132:264-278.
Brewer GJ, Askari F, Lorincz MT, et al. Treatment of Wilson disease with ammonium tetrathiomolybdate: IV. comparison of tetrathiomolybdate and trientine in a double-blind study of treatment of the neurologic presentation of Wilson disease. Arch Neurol. 2006;63:521-527.
1. Bull PC, Thomas GR, Rommens JM, et al. The Wilson disease gene is a putative copper transporting P-type ATPase similar to the Menkes gene. Nat Genet. 1993;5:327-337.
2. Tanzi RE, Petrukhin K, Chernov I, et al. The Wilson disease gene is a copper transporting ATPase with homology to the Menkes disease gene. Nat Genet. 1993;5:344-350.
3. Yamaguchi Y, Heiny ME, Gitlin JD. Isolation and characterization of a human liver cDNA as a candidate gene for Wilson disease. Biochem Biophys Res Commun. 1993;197:271-277.
4. Askari FK, Greenson J, Dick RD, et al. Treatment of Wilson's disease with zinc. XVIII. initial treatment of the hepatic decompensation presentation with trientine and zinc. J Lab Clin Med. 2003;142:385-390.
5. Nazer H, Ede RJ, Mowat AP, et al. Wilson's disease: clinical presentation and use of prognostic index. Gut. 1986;27:1377-1381.
6. Starosta-Rubinstein S, Young AB, Kluin K, et al. Clinical assessment of 31 patients with Wilson's disease: correlations with structural changes on magnetic resonance imaging. Arch Neurol. 1987;44:365-370.
7. Brewer GJ. Behavioral abnormalities in Wilson's disease. In: Weiner WJ, Lang AE, Anderson KE, eds. Behavioral neurology of movement disorders. 2nd ed. Philadelphia, PA: Lippincott, Williams & Wilkins, 2005:262-274.
8. Dedoussis GV, Genschel J, Sialvera TE, et al. Wilson disease: high prevalence in a mountainous area of Crete. Ann Hum Genet. 2005;69:268-274.
9. Brewer GJ. Wilson's disease: a clinician's guide to recognition, diagnosis, and management. Boston, MA: Kluwer Academic Publishers, 2001.
10. Hoogenraad TU. Wilson's disease. London, UK: Saunders, 1996.
11. Scheinberg IH, Sternlieb I. Wilson's disease. In: Smith LHJ, ed. Major problems in internal medicine. Vol 23. Philadelphia, PA: WB Saunders, 1984:1-171.
12. Ala A, Borjigin J, Rochwarger A, et al. Wilson disease in septuagenarian siblings: raising the bar for diagnosis. Hepatology. 2005;41:668-670.
13. Cox DW, Roberts E. Wilson disease. Seattle: GeneClinics, University of Washington; 2006.
14. Brewer GJ, Yuzbasiyan-Gurkan V. Wilson disease. Medicine Baltimore. 1992;71:139-164.
15. Brewer GJ, Yuzbasiyan-Gurkan V, Dick R, et al. Does a vegetarian diet control Wilson's disease? J Am Coll Nutr. 1993;12:527-530.
16. Brewer GJ. Recognition, diagnosis, and management of Wilson's disease. Proc Soc Exp Biol Med. 2000;223:39-46.
17. Brewer GJ. Wilson's disease. In: Kasper DL, Braunward E, Fauci AS, et al, eds. Harrison's principles of internal medicine. 16th ed. New York, NY: McGraw-Hill Companies, 2004:2313-2315.
18. Brewer GJ. Novel therapeutic approaches to the treatment of Wilson's disease. Exp Opin Pharmacother. 2006;7:317-324.
19. Merle U, Eisenbach C, Weiss KH, et al. Serum ceruloplasmin oxidase activity is a sensitive and highly specific diagnostic marker for Wilson's disease. J Hepatol. 2009;51:925-930.
20. McMillin GA, Travis JJ, Hunt JW. Direct measurement of free copper in serum or plasma ultrafiltrate. Am J Clin Pathol. 2009;131:160-165.
21. Hedera P. Update on the clinical management of Wilson's disease. Appl Clin Genet. 2017 Jan 13;10:9-19.
22. Roberts EA, Schilsky ML; American Association for Study of Liver Diseases (AASLD). Diagnosis and treatment of Wilson disease: an update. Hepatology. 2008;47:2089-2111.
23. Dhawan A, Taylor RM, Cheeseman P, et al. Wilson's disease in children: 37-year experience and revised King's score for liver transplantation. Liver Transpl. 2005;11:441-448.
24. Walshe JM. Treatment of Wilson's disease with trientine (triethylene tetramine) dihydrochloride. Lancet. 1982;1:643-647.
25. Brewer GJ, Dick RD, Johnson VD, et al. Treatment of Wilson's disease with zinc: XV long-term follow-up studies. J Lab Clin Med. 1998;132:264-278.
26. Walshe JM. Penicillamine, a new oral therapy for Wilson's disease. Am J Med. 1956;21:487-495.
27. Brewer GJ, Terry CA, Aisen AM, et al. Worsening of neurologic syndrome in patients with Wilson's disease with initial penicillamine therapy. Arch Neurol. 1987;44:490-493.
28. Brewer GJ, Askari F, Lorincz MT, et al. Treatment of Wilson disease with ammonium tetrathiomolybdate: IV. comparison of tetrathiomolybdate and trientine in a double-blind study of treatment of the neurologic presentation of Wilson disease. Arch Neurol. 2006;63:521-527.
29. Brewer GJ, Hedera P, Kluin KJ, et al. Treatment of Wilson disease with ammonium tetrathiomolybdate: III. initial therapy in a total of 55 neurologically affected patients and follow-up with zinc therapy. Arch Neurol. 2003;60:379-385.
使用此内容应接受我们的免责声明。
BMJ临床实践的持续改进离不开您的帮助和反馈。如果您发现任何功能问题和内容错误,或您对BMJ临床实践有任何疑问或建议,请您扫描右侧二维码并根据页面指导填写您的反馈和联系信息*。一旦您的建议在我们核实后被采纳,您将会收到一份小礼品。
如果您有紧急问题需要我们帮助,请您联系我们。
邮箱:bmjchina.support@bmj.com
电话:+86 10 64100686-612
*您的联系信息仅会用于我们与您确认反馈信息和礼品事宜。
BMJ临床实践官方反馈平台